• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

846
68
51
50
30

COUNTRY

30
13
13
12
12

PRICE

681
866
964
1,564

PUBLISHED

16
58
323
1,564

PRODUCT TYPE

959
499
86
16
2
2

Infectious Diseases

Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed under Research and Markets’ Infectious Diseases category.

Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.

For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices. Show Less
Read more

PRODUCT TITLE

Haemophilus Influenzae Infections - Pipeline Review, H2 2013

Haemophilus Influenzae Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Haemophilus Influenzae Infections - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Francisella Tularensis Infections - Pipeline Review, H2 2013

Francisella Tularensis Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Francisella Tularensis Infections - Pipeline Review, H2 2013', provides an overview of the indication’s...

December 2013
FROM

Community-Acquired Infections - Pipeline Review, H2 2013

Community-Acquired Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Community-Acquired Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

December 2013
FROM

Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013

Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Genital Warts (Condylomata Acuminata) Global Clinical Trials Review, H2, 2013" provides...

December 2013
FROM

Endotoxemia Global Clinical Trials Review, H2, 2013

Endotoxemia Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Endotoxemia Global Clinical Trials Review, H2, 2013" provides data on the Endotoxemia clinical trial scenario....

December 2013
FROM

Pertussis Global Clinical Trials Review, H2, 2013

Pertussis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Pertussis Global Clinical Trials Review, H2, 2013" provides data on the Pertussis clinical trial scenario. This...

December 2013
FROM

Bacteremia Global Clinical Trials Review, H2, 2013

Bacteremia Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Bacteremia Global Clinical Trials Review, H2, 2013" provides data on the Bacteremia clinical trial scenario....

December 2013
FROM
Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - Consensus Outlook Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - Consensus Outlook - Product Thumbnail Image

Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - Consensus Outlook

The worldwide hepatitis C (HCV) market is forecast to grow from $4 7 billion in 2012 to $17 7 billion in 2017 The catalysts for this growth include a boost in diagnosis rates following an increase in...

December 2013
FROM
Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - KOL Insight Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - KOL Insight - Product Thumbnail Image

Hepatitis C: Game Changing Regimens to Revolutionise Treatment Landscape - KOL Insight

The December 2013 approval of Gilead's once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV) With efficacy over 90% in GT1/2/3/4 patients, this...

December 2013
FROM

Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013

Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2013', provides an overview of...

November 2013
FROM

Acinetobacter Infections - Pipeline Review, H2 2013

Acinetobacter Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Acinetobacter Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

November 2013
FROM

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review,...

November 2013
FROM

Enterovirus Infections - Pipeline Review, H2 2013

Enterovirus Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Enterovirus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

November 2013
FROM

Mumps - Pipeline Review, H2 2013

'Mumps - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development for Mumps, complete with latest updates,...

November 2013
FROM

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2013

Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Severe Acute Respiratory Syndrome (SARS) Coronavirus Infection - Pipeline...

November 2013
FROM

West Nile Virus Infections - Pipeline Review, H2 2013

West Nile Virus Infections - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'West Nile Virus Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

November 2013
FROM

Tetanus Global Clinical Trials Review, H2, 2013

Tetanus Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Tetanus Global Clinical Trials Review, H2, 2013" provides data on the Tetanus clinical trial scenario. This report...

November 2013
FROM

Filariasis Global Clinical Trials Review, H2, 2013

Filariasis Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Filariasis Global Clinical Trials Review, H2, 2013" provides data on the Filariasis clinical trial scenario....

November 2013
FROM

Shigella Infections (Shigellosis) Global Clinical Trials Review, H2, 2013

Shigella Infections (Shigellosis) Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Shigella Infections (Shigellosis) Global Clinical Trials Review, H2, 2013" provides data...

November 2013
FROM

EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022

EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022 Summary Urinary tract infections (UTIs) are among the most common bacterial infections acquired in hospitals...

November 2013
FROM
Loading Indicator

Our Clients

Our clients' logos